From: An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials
End point | Â | nj | 3 | 6 | 9 | 12 | 15 | 18 | 21 | 24 | 27 | 30 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bernoulli | Ď•0=0.2 | \(\lambda _{e}^{*}{(n_{j})}\) | 0.16 | 0.16 | 0.16 | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 |
or | Â | \(\lambda _{d}^{*}{(n_{j})}\) | 0.24 | 0.24 | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 |
quasi- | Ď•0=0.3 | \(\lambda _{e}^{*}{(n_{j})}\) | 0.24 | 0.24 | 0.24 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.26 | 0.26 |
Bernoulli | Â | \(\lambda _{d}^{*}{(n_{j})}\) | 0.36 | 0.36 | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.32 |
Continuous | Ď•0=0.2 | \(\lambda _{e}^{*}{(n_{j})}\) | 0.16 | 0.16 | 0.17 | 0.17 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 |
 |  | \(\lambda _{d}^{*}{(n_{j})}\) | 0.24 | 0.24 | 0.22 | 0.21 | 0.21 | 0.21 | 0.21 | 0.21 | 0.21 | 0.21 |
 | ϕ0=0.3 | \(\lambda _{e}^{*}{(n_{j})}\) | 0.24 | 0.24 | 0.26 | 0.26 | 0.27 | 0.27 | 0.27 | 0.27 | 0.27 | 0.27 |
 |  | \(\lambda _{d}^{*}{(n_{j})}\) | 0.36 | 0.36 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 |